ICTU

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2

Retrieved on: 
Wednesday, July 12, 2023

George Medicines’ mission is to extend and improve the lives of the millions of people suffering from non-communicable cardiometabolic diseases – the world’s leading causes of death and disability, including hypertension and diabetes.

Key Points: 
  • George Medicines’ mission is to extend and improve the lives of the millions of people suffering from non-communicable cardiometabolic diseases – the world’s leading causes of death and disability, including hypertension and diabetes.
  • Globally, over a billion people worldwide have hypertension but fewer than one in five have the condition under control.
  • GMRx2 is formulated in novel, patent-protected low and ultra-low doses, to be a simple, go-to solution to reach targeted blood pressure control across different patient types.
  • Dr. Karl Roberts, Chief Operating Officer of George Medicines, said: “The progress of this Phase III programme is a huge testament to the dedication of the team and our partners working to bring GMRx2 to patients.

Empowering Clinical Trial Sites to Deliver Better Clinical Data, Faster: Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, April 26, 2022

TORONTO, April 26, 2022 /PRNewswire-PRWeb/ -- With the clinical research space evolving at lightning speed, clinical trial sponsors and research sites may be overwhelmed when trying to scale and accelerate their trials to collect clinical data quickly and accurately. Enter technology.

Key Points: 
  • Attendees will learn methodologies for technology adoption among sites (clinical research coordinators, clinical data managers, monitors, and biostatisticians) that help reduce burnout.
  • TORONTO, April 26, 2022 /PRNewswire-PRWeb/ -- With the clinical research space evolving at lightning speed, clinical trial sponsors and research sites may be overwhelmed when trying to scale and accelerate their trials to collect clinical data quickly and accurately.
  • In this webinar, a panel of clinical trial experts come together to discuss the role that technology plays in clinical data capture.
  • For more information, or to register for this event, visit Empowering Clinical Trial Sites to Deliver Better Clinical Data, Faster.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

Retrieved on: 
Monday, January 17, 2022

The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.

Key Points: 
  • The phase III trial is the final stage of development, with results expected to support a regulatory filing for approval.
  • Professor Ray leads a team of highly experienced operational staff to deliverexcellence in clinical trial management.
  • We are delighted to collaborate with Imperial Clinical Trials Unit to expand our research into the UK, where high blood pressure remains a significant silent killer and many patients are still uncontrolled.
  • A therapy that can more effectively control a patients blood pressure and reduce the significant pill burden that can lead patients to discontinue therapy could help transform how we treat high blood pressure.